tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Staar Surgical Amends Merger Agreement with Alcon

Story Highlights
  • STAAR Surgical amended its merger agreement with Alcon to allow a 30-day go-shop period.
  • The special stockholder meeting was postponed to December 19, 2025, to consider new proposals.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Staar Surgical Amends Merger Agreement with Alcon

Meet Your ETF AI Analyst

The latest announcement is out from Staar Surgical ( (STAA) ).

On November 7, 2025, STAAR Surgical Company announced an amendment to its merger agreement with Alcon Inc., introducing a 30-day go-shop period allowing STAAR to solicit third-party acquisition proposals. This amendment, which includes no termination fee for accepting a superior proposal and Alcon waiving matching rights, aims to maximize shareholder value by encouraging competitive offers. The special meeting of STAAR stockholders to vote on the merger proposal has been postponed to December 19, 2025, to accommodate this process.

The most recent analyst rating on (STAA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

Staar Surgical’s overall stock score is primarily impacted by its financial performance and valuation concerns. The company’s declining revenue and profitability, coupled with a negative P/E ratio, highlight significant operational and valuation challenges. Technical analysis provides a neutral outlook, with no strong momentum indicators. The absence of earnings call data and corporate events leaves some uncertainty about future strategic directions.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical, headquartered in Lake Forest, California, is a global leader in implantable phakic intraocular lenses (ICLs), which provide vision correction without the need for glasses or contact lenses. The company has been dedicated to ophthalmic surgery since 1982 and has sold over 3 million ICLs in more than 75 countries. STAAR’s EVO family of Implantable Collamer Lenses is known for its minimally invasive procedure and long-term safety.

Average Trading Volume: 1,015,692

Technical Sentiment Signal: Sell

Current Market Cap: $1.25B

For detailed information about STAA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1